

Jon A Kobashigawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2063779/publications.pdf>

Version: 2024-02-01

381
papers

23,578
citations

11639

70
h-index

9579

142
g-index

399
all docs

399
docs citations

399
times ranked

12896
citing authors

#	ARTICLE	IF	CITATIONS
1	Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1710-1720.	0.3	1,538
2	The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 914-956.	0.3	1,385
3	Effect of Pravastatin on Outcomes after Cardiac Transplantation. <i>New England Journal of Medicine</i> , 1995, 333, 621-627.	13.9	1,215
4	Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. <i>New England Journal of Medicine</i> , 2003, 349, 847-858.	13.9	1,104
5	Listing Criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidatesâ€”2006. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1024-1042.	0.3	850
6	International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathyâ€”2010. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 717-727.	0.3	719
7	A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS ¹ . <i>Transplantation</i> , 1998, 66, 507-515.	0.5	545
8	Report from a consensus conference on primary graft dysfunction after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 327-340.	0.3	523
9	Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 2577-2584.	6.3	398
10	Multicenter Intravascular Ultrasound Validation Study Among Heart Transplant Recipients. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1532-1537.	1.2	372
11	Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 58-69.	0.3	363
12	Report from a consensus conference on antibody-mediated rejection in heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 252-269.	0.3	328
13	Importance of hemodynamic response to therapy in predicting survival with ejection fraction â‰¥ 20% secondary to ischemic or nonischemic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1990, 66, 1348-1354.	0.7	321
14	HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION. <i>Transplantation</i> , 1997, 63, 331-338.	0.5	289
15	Acute Antibody-mediated Rejection of Cardiac Transplants. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 153-159.	0.3	274
16	Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management. <i>Circulation</i> , 2015, 131, 1608-1639.	1.6	268
17	A Controlled Trial of Exercise Rehabilitation after Heart Transplantation. <i>New England Journal of Medicine</i> , 1999, 340, 272-277.	13.9	246
18	Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 517-525.	0.3	237

#	ARTICLE	IF	CITATIONS
19	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	2.6	205
20	Drug Therapy in the Heart Transplant Recipient. Circulation, 2004, 110, 3858-3865.	1.6	200
21	The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005â€“2011). Journal of Heart and Lung Transplantation, 2011, 30, 601-611.	0.3	193
22	THE EFFECT OF PRAVASTATIN ON ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION-A PILOT STUDY1. Transplantation, 1996, 61, 1469-1474.	0.5	192
23	Asymptomatic Antibody-mediated Rejection After Heart Transplantation Predicts Poor Outcomes. Journal of Heart and Lung Transplantation, 2009, 28, 417-422.	0.3	190
24	Ten-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients. Journal of Heart and Lung Transplantation, 2005, 24, 1736-1740.	0.3	165
25	Report From a Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 213-225.	0.3	158
26	Honoring 50 Years of Clinical Heart Transplantation in <i>Circulation</i>. Circulation, 2018, 137, 71-87.	1.6	154
27	Drug Therapy in the Heart Transplant Recipient. Circulation, 2004, 110, 3734-3740.	1.6	153
28	Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 1320-1326.	0.3	145
29	Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study. American Journal of Transplantation, 2019, 19, 2889-2899.	2.6	138
30	Predicted heart mass is the optimal metric for size match in heart transplantation. Journal of Heart and Lung Transplantation, 2019, 38, 156-165.	0.3	138
31	Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clinical Transplantation, 2007, 22, 070618134134002-???.	0.8	136
32	Task force 5: Complications. Journal of the American College of Cardiology, 1993, 22, 41-54.	1.2	129
33	FLOW CYTOMETRIC DETECTION OF HLA-SPECIFIC ANTIBODIES AS A PREDICTOR OF HEART ALLOGRAFT REJECTION1. Transplantation, 2000, 70, 1055-1059.	0.5	126
34	INHALED NITRIC OXIDE FOR PULMONARY HYPERTENSION AFTER HEART TRANSPLANTATION. Transplantation, 2001, 72, 638-641.	0.5	123
35	Molecular Testing in the Management of Cardiac Transplant Recipients: Initial Clinical Experience. Journal of Heart and Lung Transplantation, 2006, 25, 1389-1395.	0.3	114
36	Supraventricular Tachycardia After Orthotopic Cardiac Transplantation. Journal of the American College of Cardiology, 2008, 51, 2241-2249.	1.2	114

#	ARTICLE	IF	CITATIONS
37	The management of antibodies in heart transplantation: An ISHLT consensus document. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 537-547.	0.3	114
38	Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 701-708.	0.3	110
39	Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. <i>Current Opinion in Cardiology</i> , 2004, 19, 166-169.	0.8	110
40	Cardiac Allograft Vasculopathy by Intravascular Ultrasound in Heart Transplant Patients. <i>JACC: Heart Failure</i> , 2013, 1, 389-399.	1.9	110
41	Retransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 862-868.	0.3	105
42	Increased Negative Impact of Donor HLA-Specific Together With Non-HLA-Specific Antibodies on Graft Outcome. <i>Transplantation</i> , 2014, 97, 595-601.	0.5	105
43	Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations. <i>American Journal of Transplantation</i> , 2018, 18, 30-42.	2.6	105
44	HLA and MICA: Targets of Antibody-Mediated Rejection in Heart Transplantation. <i>Transplantation</i> , 2011, 91, 1153-1158.	0.5	99
45	Five-Year Results of a Randomized, Single-Center Study of Tacrolimus vs Microemulsion Cyclosporine in Heart Transplant Patients. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 434-439.	0.3	93
46	Interagency registry for mechanically assisted circulatory support report on the total artificial heart. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1304-1312.	0.3	92
47	The Past, Present and Future of Heart Transplantation. <i>Korean Circulation Journal</i> , 2018, 48, 565.	0.7	92
48	Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 504-508.	0.3	91
49	Diverse morphologic manifestations of cardiac allograft vasculopathy: A pathologic study of 64 allograft hearts. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1044-1050.	0.3	91
50	The long-term outcome of treated sensitized patients who undergo heart transplantation. <i>Clinical Transplantation</i> , 2011, 25, E61-E67.	0.8	91
51	Decreasing survival benefit from cardiac transplantation for outpatients as the waiting list lengthens. <i>Journal of the American College of Cardiology</i> , 1991, 18, 919-925.	1.2	90
52	Sensitization in Heart Transplantation: Emerging Knowledge: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e553-e578.	1.6	89
53	Arrhythmias After Heart Transplantation: Mechanisms and Management. <i>Journal of the American Heart Association</i> , 2012, 1, e001461.	1.6	88
54	Use of two recipient lists for adults requiring heart transplantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 125, 49-59.	0.4	87

#	ARTICLE	IF	CITATIONS
55	Peri-operative Renal Function and Outcome after Orthotopic Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 162-166.	0.3	87
56	Multicenter Retrospective Analysis of Cardiovascular Risk Factors Affecting Long-term Outcome of De Novo Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1063-1069.	0.3	84
57	Cardiac allograft rejection. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2011, 9, 160-167.	0.8	84
58	Early Denervation and Later Reinnervation of the Heart Following Cardiac Transplantation: A Review. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	83
59	Heart transplant recipients supported with extracorporeal membrane oxygenation: Outcomes from a single-center experience. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1250-1256.	0.3	82
60	Cardiac Transplantation. <i>JACC: Heart Failure</i> , 2017, 5, 857-868.	1.9	79
61	Patterns and Predictors of Quality of Life at 5 to 10 Years After Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 535-543.	0.3	77
62	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002572.	3.9	76
63	A Lower Incidence of Cytomegalovirus Infection in De Novo Heart Transplant Recipients Randomized to Everolimus. <i>Transplantation</i> , 2007, 84, 1436-1442.	0.5	74
64	Randomized Pilot Trial of Gene Expression Profiling Versus Heart Biopsy in the First Year After Heart Transplant. <i>Circulation: Heart Failure</i> , 2015, 8, 557-564.	1.6	74
65	Mitral regurgitation after cardiac transplantation. <i>American Journal of Cardiology</i> , 1987, 60, 119-122.	0.7	73
66	High density associated enzymes: their role in vascular biology. <i>Current Opinion in Lipidology</i> , 1998, 9, 449-456.	1.2	73
67	Prevention of Post-transplant Cardiovascular Disease - Report and Recommendations of an Ad Hoc Group1. <i>American Journal of Transplantation</i> , 2002, 2, 491-500.	2.6	71
68	Hepatitis C-positive Donors in Heart Transplantation. <i>American Journal of Transplantation</i> , 2002, 2, 443-447.	2.6	71
69	Sudden, unexpected death in cardiac transplant recipients: an autopsy study. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 683-689.	0.3	71
70	Immunoperoxidase Staining for C4d on Paraffin-embedded Tissue in Cardiac Allograft Endomyocardial Biopsies. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2004, 12, 166-171.	0.6	71
71	Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 787-796.	0.3	71
72	Effects of Cardiac Allograft Vasculopathy on Myocardial Blood Flow, Vasodilatory Capacity, and Coronary Vasomotion. <i>Circulation</i> , 1997, 95, 600-606.	1.6	71

#	ARTICLE	IF	CITATIONS
73	Temporal Trends of De Novo Malignancy Development After Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 40-49.	1.2	70
74	Heart transplantation in patients with diabetes mellitus in the current era. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 1091-1097.	0.3	68
75	Influence of Pre-Existing Donor Atherosclerosis on the Development of Cardiac Allograft Vasculopathy and Outcomes in Heart Transplant Recipients. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2470-2476.	1.2	68
76	An overview of frailty in kidney transplantation: measurement, management and future considerations. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1099-1112.	0.4	68
77	Increased incidence of atrial flutter associated with the rejection of heart transplantation. <i>American Journal of Cardiology</i> , 2001, 88, 280-284.	0.7	64
78	Similar Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS, Myfortic) Compared With Mycophenolate Mofetil (MMF) in De Novo Heart Transplant Recipients: Results of a 12-Month, Single-blind, Randomized, Parallel-group, Multicenter Study. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 935-941.	0.3	61
79	Intermediate outcomes with ex-vivo allograft perfusion for heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 258-263.	0.3	61
80	Elevated Serum Levels of the CXCR3 Chemokine ITAC Are Associated With the Development of Transplant Coronary Artery Disease. <i>Circulation</i> , 2003, 107, 1958-1961.	1.6	60
81	Mode and mechanisms of death after orthotopic heart transplantation. <i>Heart Rhythm</i> , 2009, 6, 503-509.	0.3	60
82	Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 1999, 18, 211-219.	0.3	59
83	The use of donor hearts with left ventricular hypertrophy. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 496-503.	0.3	58
84	Chagas disease in solid organ and heart transplantation. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 418-424.	1.3	58
85	Comparison of Percutaneous Coronary Intervention With Bare-Metal and Drug-Eluting Stents for Cardiac Allograft Vasculopathy. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 710-715.	1.1	57
86	Heart Transplantation for End-Stage Heart Failure Due to Cardiac Sarcoidosis. <i>Transplantation Proceedings</i> , 2013, 45, 2384-2386.	0.3	57
87	Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 546-550.	0.3	56
88	The Economic Implications of Noninvasive Molecular Testing for Cardiac Allograft Rejection. <i>American Journal of Transplantation</i> , 2005, 5, 1553-1558.	2.6	56
89	Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: a multicenter prospective intravascular ultrasound study. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 385-392.	0.3	55
90	Heart Transplantation for Chagas Cardiomyopathy in the United States. <i>American Journal of Transplantation</i> , 2013, 13, 3262-3268.	2.6	55

#	ARTICLE	IF	CITATIONS
91	Use of hearts transplanted from donors with atraumatic intracranial bleeds. Journal of Heart and Lung Transplantation, 2002, 21, 623-628.	0.3	54
92	Statins in Solid Organ Transplantation: Is There an Immunosuppressive Effect?. American Journal of Transplantation, 2004, 4, 1013-1018.	2.6	54
93	Perceptions and Practices Regarding Frailty in Kidney Transplantation: Results of a National Survey. Transplantation, 2020, 104, 349-356.	0.5	54
94	Outcome of hearts with cold ischemic time greater than 300minutes. A case-matched study. European Journal of Cardio-thoracic Surgery, 2005, 28, 143-148.	0.6	53
95	Updates on Heart Transplantation. Current Heart Failure Reports, 2019, 16, 150-156.	1.3	53
96	Quantification of absolute myocardial perfusion at rest and during exercise with positron emission tomography after human cardiac transplantation. Journal of the American College of Cardiology, 1991, 18, 512-517.	1.2	51
97	Prediction of heart transplant rejection with a breath test for markers of oxidative stress. American Journal of Cardiology, 2004, 94, 1593-1594.	0.7	50
98	Angiotensin-Converting Enzyme Inhibition Early After Heart Transplantation. Journal of the American College of Cardiology, 2017, 69, 2832-2841.	1.2	50
99	Imaging in Heart Transplant Patients. JACC: Cardiovascular Imaging, 2018, 11, 1514-1530.	2.3	50
100	Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation. Circulation, 2020, 141, 1954-1967.	1.6	50
101	Consensus conference on heart-kidney transplantation. American Journal of Transplantation, 2021, 21, 2459-2467.	2.6	49
102	The Revised ISHLT Heart Biopsy Grading Scale. Journal of Heart and Lung Transplantation, 2005, 24, 1709.	0.3	48
103	Should we be doing routine biopsy after heart transplantation in a new era of anti-rejection?. Current Opinion in Cardiology, 2006, 21, 127-131.	0.8	48
104	Seventeen-year experience with 1,083 heart transplants at a single institution. Annals of Thoracic Surgery, 2002, 74, 1558-1567.	0.7	47
105	Usefulness and Safety of Percutaneous Coronary Interventions for Cardiac Transplant Vasculopathy. American Journal of Cardiology, 2006, 97, 1192-1197.	0.7	47
106	Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. Journal of Heart and Lung Transplantation, 2016, 35, 165-172.	0.3	47
107	What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?. , 2000, 1, 166.		46
108	Review of Major Clinical Trials with Mycophenolate Mofetil in Cardiac Transplantation. Transplantation, 2005, 80, S235-S243.	0.5	46

#	ARTICLE	IF	CITATIONS
109	Hope, mood states and quality of life in female heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 681-686.	0.3	45
110	Functional status and perceived control influence quality of life in female heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 360-367.	0.3	44
111	Immunosuppression for heart transplantation: where are we now?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 203-212.	3.3	44
112	Amiodarone therapy does not compromise subsequent heart transplantation. <i>Journal of the American College of Cardiology</i> , 1992, 20, 1556-1561.	1.2	43
113	An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 636-646.	0.3	43
114	A New Paradigm in Mechanical Circulatory Support: 100-Patient Experience. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1370-1377.	0.7	43
115	Exploring the cardiac response to injury in heart transplant biopsies. <i>JCI Insight</i> , 2018, 3, .	2.3	43
116	Recent Trends in Early Outcome of Adult Patients after Heart Transplantation: A Single-institution Review of 251 Transplants Using Standard Donor Organs ¹ . <i>American Journal of Transplantation</i> , 2002, 2, 539-545.	2.6	42
117	First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 711-714.	0.3	41
118	Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2479-2488.	2.6	41
119	Results after transplantation using donor hearts with preexisting coronary artery disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 821-825.	0.4	40
120	Donor-recipient sex mismatch portends poor 10-year outcomes in a single-center experience. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1018-1022.	0.3	40
121	Cardiac Allograft Vasculopathy: The Enduring Enemy of Cardiac Transplantation. <i>Transplantation</i> , 2019, 103, 1338-1348.	0.5	40
122	Effects of Older Donor Age and Cold Ischemic Time on Long-Term Outcomes of Heart Transplantation. <i>Texas Heart Institute Journal</i> , 2018, 45, 17-22.	0.1	40
123	Psychiatric disorders and outcome following cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 1999, 18, 952-956.	0.3	39
124	Cardiac transplantation: the alternate list and expansion of the donor pool. <i>Current Opinion in Cardiology</i> , 2004, 19, 162-165.	0.8	39
125	Symptomatic Osteonecrosis of the Hip and Knee After Cardiac Transplantation. <i>Journal of Arthroplasty</i> , 2008, 23, 90-96.	1.5	39
126	Has the 2004 revision of the International Society of Heart and Lung Transplantation grading system improved the reproducibility of the diagnosis and grading of cardiac transplant rejection?. <i>Cardiovascular Pathology</i> , 2009, 18, 198-204.	0.7	39

#	ARTICLE	IF	CITATIONS
127	In vivo diffusion-tensor MRI of the human heart on a 3 tesla clinical scanner: An optimized second order (M2) motion compensated diffusion-preparation approach. <i>Magnetic Resonance in Medicine</i> , 2016, 76, 1354-1363.	1.9	39
128	Clinical Implications and Longitudinal Alteration of Peripheral Blood Transcriptional Signals Indicative of Future Cardiac Allograft Rejection. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 297-301.	0.3	38
129	Antibody-mediated rejection. <i>Current Opinion in Organ Transplantation</i> , 2012, 17, 551-557.	0.8	38
130	Correlation between myocardial fibrosis and restrictive cardiac physiology in patients undergoing retransplantation. <i>Clinical Transplantation</i> , 2013, 27, E679-84.	0.8	38
131	Echocardiographic parameters associated with right ventricular failure after left ventricular assist device: A review. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 283-293.	0.3	38
132	Characterizing Predictors and Severity of Vasoplegia Syndrome After Heart Transplantation. <i>Annals of Thoracic Surgery</i> , 2018, 105, 770-777.	0.7	38
133	Patterns and Predictors of Physical Functional Disability at 5 to 10 Years After Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 1182-1191.	0.3	37
134	Heart Transplantation With and Without Prior Sternotomy: Analysis of the United Network for Organ Sharing Database. <i>Transplantation Proceedings</i> , 2014, 46, 249-255.	0.3	37
135	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 36-51.	1.2	37
136	Differential expression of RANTES chemokine, TGF- β 2, and leukocyte phenotype in acute cellular rejection and quilty B lesions. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 407-416.	0.3	35
137	Report From a Forum on US Heart Allocation Policy. <i>American Journal of Transplantation</i> , 2015, 15, 55-63.	2.6	35
138	Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization. <i>JAMA Cardiology</i> , 2018, 3, 1206.	3.0	35
139	The prevalence of calcified carotid atheromas on the panoramic radiographs of patients with dilated cardiomyopathy. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2004, 97, 404-407.	1.6	34
140	Gene Expression Profiling Distinguishes a Molecular Signature for Grade 1B Mild Acute Cellular Rejection in Cardiac Allograft Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 1270-1280.	0.3	34
141	Use of Hearts Transplanted From Donors With Severe Sepsis and Infectious Deaths. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 260-265.	0.3	34
142	Vasoplegia after heart transplantation: outcomes at 1 year. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 25, 212-217.	0.5	34
143	Device Strategies for Patients in INTERMACS Profiles 1 and 2 Cardiogenic Shock: Double Bridge With Extracorporeal Membrane Oxygenation and Initial Implant of More Durable Devices. <i>Artificial Organs</i> , 2017, 41, 224-232.	1.0	34
144	Failing the Failing Heart: A Review of Palliative Care in Heart Failure. <i>Reviews in Cardiovascular Medicine</i> , 2013, 14, 41-48.	0.5	34

#	ARTICLE	IF	CITATIONS
145	The Future of Heart Transplantation. American Journal of Transplantation, 2012, 12, 2875-2891.	2.6	33
146	Combined Heart and Liver Transplantation: The Cedars-Sinai Experience. Transplantation Proceedings, 2015, 47, 2722-2726.	0.3	33
147	Marijuana and Listing for Heart Transplant. Circulation: Heart Failure, 2016, 9, .	1.6	33
148	Evolving Areas in Heart Transplantation. JACC: Heart Failure, 2017, 5, 869-878.	1.9	33
149	Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients. Journal of the American Heart Association, 2019, 8, e010570.	1.6	33
150	Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplantation Proceedings, 2020, 52, 2711-2714.	0.3	33
151	CAUSE OF ATRIOVENTRICULAR BLOCK IN PATIENTS AFTER HEART TRANSPLANTATION. Transplantation, 2003, 76, 137-142.	0.5	32
152	Physical Activity Patterns in Heart Transplant Women. Journal of Cardiovascular Nursing, 2005, 20, 334-339.	0.6	32
153	Induction Therapy With Antithymocyte Globulin in Patients Undergoing Cardiac Transplantation Is Associated With Decreased Coronary Plaque Progression as Assessed by Intravascular Ultrasound. Circulation: Heart Failure, 2016, 9, e002252.	1.6	32
154	Impact of Virtual Cross Match on Waiting Times for Heart Transplantation. Annals of Thoracic Surgery, 2011, 92, 2104-2111.	0.7	31
155	Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. Cardiovascular Pathology, 2020, 47, 107211.	0.7	31
156	Predictors of Quality of Life at 5 to 6 Years After Heart Transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 1431-1439.	0.3	30
157	Heterogeneity of Fibrosis in Liver Biopsies of Patients With Heart Failure Undergoing Heart Transplant Evaluation. American Journal of Surgical Pathology, 2018, 42, 1617-1624.	2.1	30
158	Mycobacterium haemophilum Infections in Heart Transplant Recipients: Case Report and Review of the Literature. American Journal of Transplantation, 2002, 2, 476-479.	2.6	29
159	Phosphorylated S6 kinase and S6 ribosomal protein are diagnostic markers of antibody-mediated rejection in heart allografts. Journal of Heart and Lung Transplantation, 2015, 34, 580-587.	0.3	29
160	Everolimus: an immunosuppressive agent in transplantation. Expert Opinion on Pharmacotherapy, 2006, 7, 1347-1355.	0.9	28
161	Transcriptional Signals of T-cell and Corticosteroid-sensitive Genes Are Associated With Future Acute Cellular Rejection in Cardiac Allografts. Journal of Heart and Lung Transplantation, 2007, 26, 1255-1263.	0.3	28
162	Long-term Outcomes of Heart Transplantation in Older Recipients. Journal of Heart and Lung Transplantation, 2008, 27, 830-834.	0.3	28

#	ARTICLE	IF	CITATIONS
163	Comparative Prognostic and Diagnostic Value of Myocardial Blood Flow and Myocardial Flow Reserve After Cardiac Transplantation. <i>Journal of Nuclear Medicine</i> , 2020, 61, 249-255.	2.8	28
164	Minimization of immunosuppression. <i>Transplant Immunology</i> , 2008, 20, 48-54.	0.6	27
165	Contemporary Left Ventricular Assist Device Outcomes in an Aging Population. <i>Journal of the American College of Cardiology</i> , 2021, 78, 883-894.	1.2	27
166	Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial. <i>Journal of the American College of Cardiology</i> , 1993, 21, 1142-1144.	1.2	26
167	Statins and Cardiac Allograft Vasculopathy after Heart Transplantation. <i>Seminars in Vascular Medicine</i> , 2004, 4, 401-406.	2.1	26
168	Clinical Outcomes of Impella Microaxial Devices Used to Salvage Cardiogenic Shock as a Bridge to Durable Circulatory Support or Cardiac Transplantation. <i>ASAIO Journal</i> , 2019, 65, 642-648.	0.9	26
169	Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside. <i>American Journal of Transplantation</i> , 2020, 20, 2768-2780.	2.6	26
170	Vascular remodelling after cardiac transplantation: a 3-year serial intravascular ultrasound study. <i>European Heart Journal</i> , 2006, 27, 1671-1677.	1.0	25
171	Factors associated with stress and coping at 5 and 10 years after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 437-446.	0.3	25
172	Combined Heart and Kidney Transplantation: A 23-Year Experience. <i>Transplantation Proceedings</i> , 2017, 49, 348-353.	0.3	25
173	Long-term clinical and angiographic outcomes of percutaneous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 48-55.	0.7	25
174	Predicting 1-year cardiac transplantation survival using a donor-recipient risk-assessment tool. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1580-1590.	0.4	25
175	Emotional adjustment 5 years after heart transplant: A multisite study. <i>Rehabilitation Psychology</i> , 2007, 52, 206-214.	0.7	24
176	The Natural History of Biopsy-Negative Rejection after Heart Transplantation. <i>Journal of Transplantation</i> , 2013, 2013, 1-6.	0.3	24
177	Mycophenolate mofetil in cardiac transplantation. <i>Current Opinion in Cardiology</i> , 1998, 13, 117-121.	0.8	23
178	Physical and psychological attributes of fatigue in female heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 614-619.	0.3	23
179	Immunosuppression following heart transplantation: prospects and challenges. <i>Immunotherapy</i> , 2014, 6, 181-194.	1.0	23
180	Left Ventricular Assist Device in Patients With Body Mass Index Greater Than 30 as Bridge to Weight Loss and Heart Transplant Candidacy. <i>Transplantation Proceedings</i> , 2014, 46, 3575-3579.	0.3	22

#	ARTICLE	IF	CITATIONS
181	Coronary Computed Tomography Angiography. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2005-2006.	1.2	22
182	Risk of deep vein thrombosis and pulmonary embolism after heart transplantation: clinical outcomes comparing upper extremity deep vein thrombosis and lower extremity deep vein thrombosis. <i>Clinical Transplantation</i> , 2015, 29, 629-635.	0.8	22
183	<i>Toxoplasma gondii</i> Serology and Outcomes After Heart Transplantation: Contention in the Literature. <i>Transplantation Proceedings</i> , 2015, 47, 1949-1953.	0.3	22
184	Use of Anti-Thymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Review. <i>Transplantation Proceedings</i> , 2017, 49, 253-259.	0.3	22
185	Mechanical circulatory support for cardiac amyloidosis. <i>Clinical Transplantation</i> , 2019, 33, e13663.	0.8	22
186	Statins as immunosuppressive agents. <i>Liver Transplantation</i> , 2001, 7, 559-561.	1.3	21
187	Vascular Remodeling 1 Year After Cardiac Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 56-62.	0.3	21
188	Long-term care of the heart transplant recipient. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 515-524.	0.8	21
189	Immunosuppression and adult heart transplantation: emerging therapies and opportunities. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 59-69.	0.6	21
190	HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients. <i>Human Immunology</i> , 2020, 81, 330-336.	1.2	21
191	Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 334-344.	0.3	21
192	Impact of De Novo Everolimus-Based Immunosuppression on Incisional Complications in Heart Transplantation. <i>Transplantation</i> , 2011, 92, 594-600.	0.5	20
193	Management of the ACC/AHA Stage D Patient. <i>Cardiology Clinics</i> , 2014, 32, 95-112.	0.9	20
194	Prior Sternotomy Increases the Mortality and Morbidity of Adult Heart Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 485-497.	0.3	19
195	Change in lymphocyte to neutrophil ratio predicts acute rejection after heart transplantation. <i>International Journal of Cardiology</i> , 2018, 251, 58-64.	0.8	19
196	Predictors of Physical Functional Disability at 5 to 6 Years after Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 2279-2285.	0.3	18
197	Tricuspid valve regurgitation after heart transplantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 1557-1559.	0.4	18
198	Recipient and surgical factors trigger severe primary graft dysfunction after heart transplant. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 970-980.	0.3	18

#	ARTICLE	IF	CITATIONS
199	Symptom Frequency and Distress from 5 to 10 Years After Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 759-768.	0.3	17
200	Management of Advanced Heart Failure. <i>Circulation</i> , 2011, 123, 1569-1574.	1.6	17
201	Extracorporeal photopheresis in heart transplant rejection. <i>Transfusion and Apheresis Science</i> , 2015, 52, 167-170.	0.5	17
202	Pathology of Chronic Chagas Cardiomyopathy in the United States. <i>American Journal of Clinical Pathology</i> , 2016, 146, 191-198.	0.4	17
203	Revealing a new mode of sensitization induced by mechanical circulatory support devices: Impact of anti-AT1R antibodies. <i>Clinical Transplantation</i> , 2018, 32, e13178.	0.8	17
204	Practice Patterns Surrounding Pregnancy After Heart Transplantation. <i>Circulation: Heart Failure</i> , 2020, 13, e006811.	1.6	17
205	Frequency of coronary artery fistulae is increased after orthotopic heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 744-746.	0.3	16
206	Clinical and Angiographic Outcomes with Everolimus Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy. <i>Journal of Interventional Cardiology</i> , 2014, 27, 73-79.	0.5	16
207	Perceived control and health-related quality of life in heart transplant recipients. <i>European Journal of Cardiovascular Nursing</i> , 2018, 17, 513-520.	0.4	16
208	Frailty in heart transplantation: Report from the heart workgroup of a consensus conference on frailty. <i>American Journal of Transplantation</i> , 2021, 21, 636-644.	2.6	16
209	<i>Ex vivo</i> normothermic perfusion in heart transplantation: a review of the TransMedics Organ Care System. <i>Future Cardiology</i> , 2022, 18, 5-15.	0.5	16
210	Heart Transplant Immunosuppression Strategies at Cedars-Sinai Medical Center. <i>International Journal of Heart Failure</i> , 2021, 3, 15.	0.9	15
211	Support with the BVS 5000 assist device during treatment of acute giant-cell myocarditis. <i>Texas Heart Institute Journal</i> , 2003, 30, 50-6.	0.1	15
212	Short-Term Bridge to Heart Transplant Using the BVS 5000 External Ventricular Assist Device1, 2. <i>American Journal of Transplantation</i> , 2002, 2, 646-651.	2.6	14
213	Strategies in Immunosuppression After Heart Transplantation. <i>Circulation: Heart Failure</i> , 2011, 4, 111-113.	1.6	14
214	Improving survival during heart transplantation: diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury. <i>Future Cardiology</i> , 2012, 8, 623-635.	0.5	14
215	Anti-Thymocyte Gamma-Globulin May Prevent Antibody Production After Heart Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 3570-3574.	0.3	14
216	Adult Heart Transplantation Following Ventricular Assist Device Implantation: Early and Late Outcomes. <i>Transplantation Proceedings</i> , 2016, 48, 158-166.	0.3	14

#	ARTICLE	IF	CITATIONS
217	Current concepts for sensitized patients before transplantation. <i>Current Opinion in Organ Transplantation</i> , 2017, 22, 236-241.	0.8	14
218	Combined heart and kidney transplantation—Is there a protective effect against cardiac allograft vasculopathy using intravascular ultrasound?. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 956-962.	0.3	14
219	Transplant centers that assess frailty as part of clinical practice have better outcomes. <i>BMC Geriatrics</i> , 2022, 22, 82.	1.1	14
220	Coronary Artery Disease in the Transplanted Heart. <i>Cardiology in Review</i> , 1996, 4, 216-225.	0.6	13
221	Contemporary Concepts in Noncellular Rejection. <i>Heart Failure Clinics</i> , 2007, 3, 11-15.	1.0	13
222	The use of the calculated panel-reactive antibody and virtual crossmatch in heart transplantation. <i>Current Opinion in Organ Transplantation</i> , 2012, Publish Ahead of Print, 423-6.	0.8	13
223	Current diagnostic and treatment strategies for cardiac allograft vasculopathy. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1147-1154.	0.6	13
224	Desensitization Strategies Pre- and Post-Cardiac Transplantation. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 8.	0.4	13
225	Desensitization strategies in the patient awaiting heart transplantation. <i>Current Opinion in Cardiology</i> , 2017, 32, 301-307.	0.8	13
226	The future of cardiac transplantation. <i>Annals of Cardiothoracic Surgery</i> , 2018, 7, 135-142.	0.6	13
227	Dual-organ transplantation in older recipients: outcomes after heart+kidney transplant versus isolated heart transplant in patients aged ≥65 years. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 45-51.	0.5	13
228	Coronary computed tomography+angiography quantitative plaque analysis improves detection of early cardiac allograft vasculopathy: A pilot study. <i>American Journal of Transplantation</i> , 2020, 20, 1375-1383.	2.6	13
229	Stem cell donor HLA typing improves CPRA in kidney allocation. <i>American Journal of Transplantation</i> , 2021, 21, 138-147.	2.6	13
230	Acceptable Post-Heart Transplant Outcomes Support Temporary MCS Prioritization in the New OPTN UNOS Heart Allocation Policy. <i>Transplantation Proceedings</i> , 2021, 53, 353-357.	0.3	13
231	Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience. <i>Transplantation Proceedings</i> , 2021, 53, 329-334.	0.3	13
232	Impact of the United Network for organ sharing 2018 donor heart allocation system on transplant morbidity and mortality. <i>Clinical Transplantation</i> , 2021, 35, e14181.	0.8	13
233	SUCCESSFUL USE OF LAMIVUDINE FOR SEVERE ACUTE HEPATITIS B VIRUS INFECTION IN A CARDIAC TRANSPLANT RECIPIENT1. <i>Transplantation</i> , 1999, 67, 1288-1289.	0.5	13
234	Immunosuppression, diagnosis, and treatment of cardiac allograft rejection. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2004, 16, 378-385.	0.4	12

#	ARTICLE	IF	CITATIONS
235	Tacrolimus in Heart Transplant Recipients. <i>BioDrugs</i> , 2007, 21, 139-143.	2.2	12
236	Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation. <i>Clinical Transplantation</i> , 2008, 22, 809-814.	0.8	12
237	Cardiac signaling molecules and plasma biomarkers after cardiac transplantation: Impact of tacrolimus versus cyclosporine. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 1222-1232.	0.3	12
238	Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support. <i>ASAIO Journal</i> , 2015, 61, 391-396.	0.9	12
239	The Search for a Gold Standard to Detect Rejection in Heart Transplant Patients. <i>Circulation</i> , 2017, 135, 936-938.	1.6	12
240	Clinical trials in heart transplantation: The evolution of evidence in immunosuppression. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1286-1290.	0.3	12
241	Accelerated Cardiac Diffusion Tensor Imaging Using Joint Low-Rank and Sparsity Constraints. <i>IEEE Transactions on Biomedical Engineering</i> , 2018, 65, 2219-2230.	2.5	12
242	Does use of intravascular ultrasound accelerate arteriopathy in heart transplant recipients?. <i>American Heart Journal</i> , 1999, 138, 358-363.	1.2	11
243	Giant cell myocarditis in a young man responsive to T-lymphocyte cytolytic therapy. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 818-821.	0.3	11
244	Successful use of a pneumatic biventricular assist device as a bridge to transplantation in cardiogenic shock. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1143-1147.	0.3	11
245	Similar Mortality and Morbidity of Orthotopic Heart Transplantation for Patients 70 Years of Age and Older Compared With Younger Patients. <i>Transplantation Proceedings</i> , 2016, 48, 2782-2791.	0.3	11
246	Total Artificial Heart as Bridge to Heart Transplantation in Chagas Cardiomyopathy: Case Report. <i>Transplantation Proceedings</i> , 2016, 48, 279-281.	0.3	11
247	Tacrolimus-associated Diffuse Gastrointestinal Ulcerations and Pathergy: A Case Report. <i>Transplantation Proceedings</i> , 2017, 49, 216-217.	0.3	11
248	Heart Transplantation for Advanced Heart Failure. , 2019, , 504-524.e2.		11
249	Plasma kallikrein predicts primary graft dysfunction after heart transplant. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1199-1211.	0.3	11
250	FK506 vs. cyclosporin. <i>Cardiovascular Pathology</i> , 2003, 12, 73-76.	0.7	10
251	The impact of mean first-year heart rate on outcomes after heart transplantation: does it make a difference?. <i>Clinical Transplantation</i> , 2013, 27, 659-665.	0.8	10
252	Total Artificial Heart Implantation as a Bridge to Heart Transplantation in an Active Duty Service Member With Amyloid Cardiomyopathy. <i>Military Medicine</i> , 2017, 182, e1858-e1860.	0.4	10

#	ARTICLE	IF	CITATIONS
253	Does ex vivo perfusion lead to more or less intimal thickening in the first year post heart transplantation?. <i>Clinical Transplantation</i> , 2019, 33, e13648.	0.8	10
254	Association of vimentin antibody and other non-HLA antibodies with treated antibody mediated rejection in heart transplant recipients. <i>Human Immunology</i> , 2020, 81, 671-674.	1.2	10
255	Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era. <i>Clinical Transplantation</i> , 2021, 35, e14308.	0.8	10
256	Diagnostic Accuracy of Cardiovascular Magnetic Resonance for Cardiac Transplant Rejection. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2337-2349.	2.3	10
257	Cardiac allograft vasculopathy: current review and future research directions. <i>Cardiovascular Research</i> , 2021, 117, 2624-2638.	1.8	10
258	Expanding the heart donor base. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 134-138.	0.8	9
259	Cutting balloon angioplasty for cardiac transplant vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 910-913.	0.3	9
260	Genetic and genomic approaches to the detection of heart transplant rejection. <i>Personalized Medicine</i> , 2012, 9, 693-705.	0.8	9
261	The policy of placing older donors into older recipients: is it worth the risk?. <i>Clinical Transplantation</i> , 2014, 28, 802-807.	0.8	9
262	Combined Heart-Kidney Transplantation After Total Artificial Heart Insertion. <i>Transplantation Proceedings</i> , 2015, 47, 210-212.	0.3	9
263	Physiology of the Transplanted Heart. , 2017, , 81-93.		9
264	Quantitative myocardial tissue characterization by cardiac magnetic resonance in heart transplant patients with suspected cardiac rejection. <i>Clinical Transplantation</i> , 2019, 33, e13704.	0.8	9
265	Impact of cytomegalovirus infection on gene expression profile in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 101-107.	0.3	9
266	Non-immune risk predictors of cardiac allograft vasculopathy: Results from the U.S. organ procurement and transplantation network. <i>International Journal of Cardiology</i> , 2021, 331, 57-62.	0.8	9
267	Thoracic Organ Transplantation: Laboratory Methods. <i>Methods in Molecular Biology</i> , 2013, 1034, 127-143.	0.4	9
268	Novel molecular approaches to the detection of heart transplant rejection. <i>Personalized Medicine</i> , 2017, 14, 293-297.	0.8	8
269	Crossing low-level donor-specific antibodies in heart transplantation. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 227-232.	0.8	8
270	Statistical performance of 16 posttransplant risk scores in a contemporary cohort of heart transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 645-656.	2.6	8

#	ARTICLE	IF	CITATIONS
271	Management of Heart Transplant Recipients: Reference for Primary Care Physicians. Postgraduate Medicine, 2012, 124, 215-224.	0.9	7
272	Toxoplasma gondii Exposure in the Heart Transplant Recipient. Transplantation, 2013, 96, 1025.	0.5	7
273	Atypical hemolytic-uremic syndrome immediately after heart transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 664-665.	0.3	7
274	Adult cardiothoracic transplant nursing: An ISHLT consensus document on the current adult nursing practice in heart and lung transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 139-148.	0.3	7
275	Socioeconomic Disparities in Heart Transplantation. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 693-694.	0.9	7
276	Antibody-mediated rejection after heart transplantation: diagnosis and clinical implications. Current Opinion in Organ Transplantation, 2020, 25, 248-254.	0.8	7
277	cBIN1 Score (CS) Identifies Ambulatory HFREF Patients and Predicts Cardiovascular Events. Frontiers in Physiology, 2020, 11, 503.	1.3	7
278	JC virus-associated nephropathy in a post-heart and kidney transplantation patient. Transplant Infectious Disease, 2020, 22, e13288.	0.7	7
279	The impact of depression on heart transplant outcomes: A retrospective single-center cohort study. Clinical Transplantation, 2021, 35, e14204.	0.8	7
280	Evolution of Testing for Allograft Rejection After Orthotopic Heart Transplantation Without the Evolution of Guidelines and a Proposal for the Multidisciplinary Health-Team Approach. American Journal of Cardiology, 2021, 149, 147-149.	0.7	7
281	The effects of donor-specific antibody characteristics on cardiac allograft vasculopathy. Clinical Transplantation, 2021, 35, e14483.	0.8	7
282	Heart Transplantation. Circulation, 2011, 124, e132-4.	1.6	6
283	Total Artificial Heart Bridge to Transplantation for a Patient With Occult Intracardiac Malignancy: Case Report. Transplantation Proceedings, 2015, 47, 2291-2294.	0.3	6
284	Corticosteroid wean after heart transplantation—Is there a risk for antibody formation?. Clinical Transplantation, 2017, 31, e12916.	0.8	6
285	Quality of Life After Heart Transplantation. , 2017, , 185-191.		6
286	Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation. American Heart Journal, 2020, 222, 30-37.	1.2	6
287	Heart Transplantation for Giant Cell Myocarditis: A Case Series. Transplantation Proceedings, 2021, 53, 348-352.	0.3	6
288	Heterogeneity of liver fibrosis in patients with congestive hepatopathy: A biopsy and explant comparison series. Annals of Diagnostic Pathology, 2022, 56, 151876.	0.6	6

#	ARTICLE	IF	CITATIONS
289	Compensatory enlargement in transplant coronary artery disease. Chinese Medical Journal, 2006, 119, 564-569.	0.9	5
290	Potential immunosuppressive effects of statins*. Pediatric Transplantation, 2008, 12, 381-384.	0.5	5
291	Retrospective review of Japanese patients undergoing heart transplantation in Japan compared with those undergoing transplantation in the United States. Journal of Heart and Lung Transplantation, 2010, 29, 1076-1078.	0.3	5
292	Prolonged QT and cardiac arrest after heart transplantation: inherited or acquired?. Journal of Electrocardiology, 2011, 44, 350-352.	0.4	5
293	Everolimus in Heart Transplantation: Does It Finally Have a Home?. American Journal of Transplantation, 2014, 14, 1719-1720.	2.6	5
294	Elevated immune monitoring early after cardiac transplantation is associated with increased plaque progression by intravascular ultrasound. Clinical Transplantation, 2015, 29, 103-109.	0.8	5
295	Elevated immune monitoring as measured by increased adenosine triphosphate production in activated lymphocytes is associated with accelerated development of cardiac allograft vasculopathy after cardiac transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 1018-1023.	0.3	5
296	Sex differences in preformed panel-reactive antibody levels and outcomes in patients undergoing heart transplantation. Clinical Transplantation, 2019, 33, e13572.	0.8	5
297	Should positron emission tomography be the standard of care for non-invasive surveillance following cardiac transplantation?. Journal of Nuclear Cardiology, 2019, 26, 655-659.	1.4	5
298	Molecular Diagnosis of Rejection in Heart Transplantation. Circulation Journal, 2022, 86, 1061-1067.	0.7	5
299	Successful Orthotopic Heart Transplantation and Immunosuppressive Management in 2 Human Immunodeficiency Virus-Seropositive Patients. Texas Heart Institute Journal, 2016, 43, 69-74.	0.1	5
300	Crossing low/moderate-level donor-specific antibodies during heart transplantation. Clinical Transplantation, 2021, 35, e14196.	0.8	5
301	Intracoronary radiation to treat in-stent restenosis in six cardiac transplant patients. Catheterization and Cardiovascular Interventions, 2003, 60, 41-44.	0.7	4
302	Prioritizing sensitized heart transplant candidates: A sensitive affair. Journal of Heart and Lung Transplantation, 2012, 31, 677-678.	0.3	4
303	Time for Change in United States Donor Heart Allocation Policy —. JACC: Heart Failure, 2014, 2, 178-179.	1.9	4
304	Detecting rejection in cardiac transplantation: applications of genomic medicine. Personalized Medicine, 2016, 13, 257-264.	0.8	4
305	Prolonged corrected QT interval in the donor heart: Is there a risk?. Clinical Transplantation, 2017, 31, e12996.	0.8	4
306	Biomarkers for Cardiac Allograft Vasculopathy. Transplantation, 2017, 101, 28-29.	0.5	4

#	ARTICLE	IF	CITATIONS
307	The ratio of circulating regulatory cluster of differentiation 4 T cells to endothelial progenitor cells predicts clinically significant acute rejection after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 496-502.	0.3	4
308	Neuroinvasive West Nile Virus Post-Heart Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2018, 50, 4057-4061.	0.3	4
309	Clinical Utility of SPECT in the Heart Transplant Population. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	4
310	Eculizumab for antibody-mediated rejection in heart transplantation: A case-control study. <i>Clinical Transplantation</i> , 2021, , e14454.	0.8	4
311	Development and validation of specific post-transplant risk scores according to the circulatory support status at transplant: A UNOS cohort analysis. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1235-1246.	0.3	4
312	Post-transplantation outcomes of sensitized patients receiving durable mechanical circulatory support. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 365-372.	0.3	4
313	Pig-to-Human Heart Transplantation: Culmination of Technology and Ingenuity. <i>Annals of Thoracic Surgery</i> , 2022, 113, 711.	0.7	4
314	Long-term preservation of functional capacity and quality of life in advanced heart failure patients with bridge to transplant therapy: A report from Japanese nationwide multicenter registry. <i>International Journal of Cardiology</i> , 2022, 356, 66-72.	0.8	4
315	Homeless donors and heart transplantation outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 355-356.	0.3	3
316	Everolimus for Cardiac Allograft Vasculopathy—Every Patient, at any Time?. <i>Transplantation</i> , 2011, 92, 127-128.	0.5	3
317	Cardiac magnetic resonance: Is it time to replace the endomyocardial biopsy to detect heart transplant rejection?. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 631-633.	0.3	3
318	Continuing the pursuit of heart transplant antibody-mediated rejection. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1134-1135.	0.3	3
319	Angiogenesis on coronary angiography is a marker for accelerated cardiac allograft vasculopathy as assessed by intravascular ultrasound. <i>Clinical Transplantation</i> , 2017, 31, e13069.	0.8	3
320	Molecular Assessment of Heart Transplant Biopsies. <i>Transplantation</i> , 2018, 102, S62-S63.	0.5	3
321	Use of durable mechanical circulatory support on outcomes of heart-kidney transplantation. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 27, 773-777.	0.5	3
322	Controversies in the Postoperative Management of the Critically Ill Heart Transplant Patient. <i>Anesthesia and Analgesia</i> , 2019, 129, 1023-1033.	1.1	3
323	Uniqueness of laryngeal nerve injury following heart transplantation. <i>Clinical Transplantation</i> , 2020, 34, e14075.	0.8	3
324	Commentary: The anticlimax of the left ventricular assist devices-associated antibodies. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 136-137.	0.4	3

#	ARTICLE	IF	CITATIONS
325	Heart transplant in Jehovah's Witness patients: A case-control study. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 575-579.	0.3	3
326	A Review of the Management of Pregnancy After Cardiac Transplantation. <i>Clinical Transplants</i> , 2015, 31, 151-161.	0.2	3
327	Influenza vaccine does not cause rejection cardiac transplantation. <i>Journal of the American College of Cardiology</i> , 1990, 15, A225.	1.2	2
328	Is an intravenous glucocorticoid pulse better than oral taper for asymptomatic cardiac rejection? A randomized trial. <i>Journal of the American College of Cardiology</i> , 1990, 15, A70.	1.2	2
329	U.S. Donor Heart Allocation Bias for Men Over Women?. <i>JACC: Heart Failure</i> , 2014, 2, 356-357.	1.9	2
330	Reducción de frecuencia en la taquicardia sinusal en pacientes con trasplante cardiaco: ¿ha llegado el momento?. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 921-923.	0.6	2
331	Leading Efforts to Increase Organ Donation Through Professionalization of Organ Procurement Organizations and Establishment of Organ and Tissue Donor Registries. <i>Transplantation Proceedings</i> , 2016, 48, 10-14.	0.3	2
332	Outpatient Management and Long-Term Complications in Heart Transplantation. , 2017, , 171-183.		2
333	Immunosuppression Strategies in Heart Transplantation. , 2017, , 109-135.		2
334	Complications After Heart Transplantation in Adults: an Update. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 27-35.	0.6	2
335	Is the Yardstick for Post-Transplant Outcomes Too Short?. <i>Circulation: Heart Failure</i> , 2019, 12, e006575.	1.6	2
336	Donor-specific antibodies in heart transplantation: can we afford the price or is it too steep to pay?. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 555-562.	0.8	2
337	The Impact of a High-risk Psychosocial Assessment on Outcomes After Durable Mechanical Circulatory Support. <i>ASAIO Journal</i> , 2021, 67, 436-442.	0.9	2
338	Long-term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single-center experience. <i>Clinical Transplantation</i> , 2022, , e14591.	0.8	2
339	HLA Homozygosity and Likelihood of Sensitization in Kidney Transplant Candidates. <i>Transplantation Direct</i> , 2022, 8, e1312.	0.8	2
340	Heart transplant recipient 1-year outcomes during the COVID-19 pandemic. <i>Clinical Transplantation</i> , 2022, 36, e14697.	0.8	2
341	Extracorporeal membrane oxygenation as a bridge to durable mechanical circulatory support or heart transplantation. <i>International Journal of Artificial Organs</i> , 2022, 45, 604-614.	0.7	2
342	Methodology of quantitating intracoronary ultrasound. <i>Journal of the American College of Cardiology</i> , 1995, 26, 303-304.	1.2	1

#	ARTICLE	IF	CITATIONS
343	Is it time for a noninvasive test to detect cardiac allograft rejection?. <i>Current Opinion in Organ Transplantation</i> , 2004, 9, 441-442.	0.8	1
344	Tacrolimus in cardiac transplantation. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 131-138.	1.3	1
345	Quest for lower immunosuppression in cardiac transplantation: an analysis of the TICTAC trial. <i>Future Cardiology</i> , 2011, 7, 293-297.	0.5	1
346	Slowing Sinus Tachycardia in Heart Transplant Recipients: Is It Time?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 921-923.	0.4	1
347	Do Prior Driveline Infections Increase the Risk of Infection in Heart Transplant Patients Treated With Rabbit Antithymocyte Globulin Induction Therapy?. <i>Transplantation Proceedings</i> , 2016, 48, 3393-3396.	0.3	1
348	Utilization of Transverse Abdominis Plexus Block for Treatment of HeartMate II Left Ventricular Assist Device-Associated Pain. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1866-1870.	0.6	1
349	Abstract 14944: Elevated Peak Immune Monitoring Early After Transplantation is Associated with Angiographic Cardiac Allograft Vasculopathy. <i>Circulation</i> , 2014, 130, .	1.6	1
350	Special Patient Populations: Transplant Recipients. , 2009, , 486-499.		1
351	“International Camaraderie” excerpts from the ISHLT 2004 presidential address. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 931-932.	0.3	0
352	Functional Status One Year After Heart Transplant. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2007, 27, 33-34.	1.2	0
353	Approach to the Sensitized Patient Awaiting Heart Transplantation. <i>Current Transplantation Reports</i> , 2014, 1, 290-299.	0.9	0
354	Cardiac allograft immune activation: current perspectives. <i>Transplant Research and Risk Management</i> , 2014, , 13.	0.7	0
355	The Changing Face of First-Year Intravascular Ultrasonography in Heart Transplantation —. <i>JACC: Heart Failure</i> , 2015, 3, 953-955.	1.9	0
356	Pediatric Heart Transplantation: Special Considerations. , 2017, , 193-211.		0
357	Immediate Post-operative Management After Heart Transplantation. , 2017, , 95-108.		0
358	Cardiac Allograft Rejection, Surveillance and Treatment. , 2017, , 157-170.		0
359	Evaluation for Heart Transplant Candidacy. , 2017, , 21-35.		0
360	Listing, Donor Allocation and Optimization of the Pre-transplant Patient. , 2017, , 37-45.		0

#	ARTICLE	IF	CITATIONS
361	The Sensitized Patient Awaiting Heart Transplantation. , 2017, , 57-71.		0
362	Donor Organ Preservation and Surgical Considerations in Heart Transplantation. , 2017, , 73-80.		0
363	Omission of heart transplant recipients from the 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease. Catheterization and Cardiovascular Interventions, 2018, 92, 451-451.	0.7	0
364	Genetic and Genomic Approaches to Predict Cardiac Allograft Rejection. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	0
365	Acute Rejection. Cardiovascular Medicine, 2019, , 255-259.	0.0	0
366	Editorial. Current Opinion in Organ Transplantation, 2019, 24, 219.	0.8	0
367	Reply: Clarifying the Utility of Myocardial Blood Flow and Myocardial Flow Reserve After Cardiac Transplantation. Journal of Nuclear Medicine, 2020, 61, 620.2-622.	2.8	0
368	Cocaine use in heart transplant donors: A call to expand the donor pool. Journal of Heart and Lung Transplantation, 2020, 39, 1351-1352.	0.3	0
369	Response by Coutance et al to Letter Regarding Article, "Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Study". Circulation, 2020, 142, e409-e410.	1.6	0
370	Omission of Heart Transplant Recipients From the Appropriate Use Criteria for Revascularization and the Ramifications on Heart Transplant Centers. JAMA Cardiology, 2020, 5, 669.	3.0	0
371	Commentary: Mechanical bridge over troubled waters. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.4	0
372	Advanced heart failure and heart transplantation in adult congenital heart disease in the current era. Clinical Transplantation, 2021, 35, e14451.	0.8	0
373	Post-transplantation outcomes of sensitized mechanical circulatory support patients. Korean Journal of Transplantation, 2021, 35, S24-S24.	0.0	0
374	Cardiac Transplantation in Patients with Congenital Heart Disease. , 2009, , 350-356.		0
375	The effects of HMG-CoA reductase inhibitors after kidney and heart transplantation: Lipid lowering and immunosuppression. , 1997, , 143-149.		0
376	Microaxial Flow Left Ventricular Assist Device as a Bridge to Transplantation after LVAD Malfunction. Texas Heart Institute Journal, 2015, 42, 572-574.	0.1	0
377	Incidence, characteristics, and outcome of post-heart transplant malignancy. Korean Journal of Transplantation, 2020, 34, S8-S8.	0.0	0
378	Immunosuppression in Cardiac Transplantation. , 2020, , 655-663.		0

#	ARTICLE	IF	CITATIONS
379	Heart transplantation in muscular dystrophy: Single-center analysis. <i>Clinical Transplantation</i> , 2022, , e14645.	0.8	0
380	Cardiac microstructural alterations in immune-inflammatory myocardial disease: a retrospective case-control study. <i>Cardiovascular Ultrasound</i> , 2022, 20, 9.	0.5	0
381	Temporary Left Ventricular Support Device as a Bridge to Heart-Liver or Heart-Kidney Transplant: Pushing the Boundaries of Temporary Support. <i>ASAIO Journal</i> , 2022, Publish Ahead of Print, .	0.9	0